Key Highlights

  • Third-quarter Revenue was USD 12.9 million, up about 11% from USD 11.6 million a year earlier and up about 13% from USD 11.4 million in the second quarter, though management said growth was below its own expectation.
  • Full-year 2026 revenue guidance was updated to USD 46 million to 48 million, which management said implies roughly 2% to 6% growth over 2025, citing a slower sales-team ramp and a shift in Y90 procedures.
  • Gross Margin improved to 86% from 84% a year ago on lower TriNav unit cost, and the adjusted EBITDA loss narrowed to about USD 4.7 million from USD 5.4 million.
  • Cash was about USD 41 million at quarter end, which management said fully funds its plan, while the 10-Q shows a third-quarter net loss of USD 8.9 million against USD 10.8 million.

Growth Misses Plan as Expansion Territories Ramp Slowly

TriSalus Life Sciences (NASDAQ:TLSI) filed its 10-Q and held its Earnings Call on November 10, 2026 for the quarter ended September 30. The company sells TriNav, a pressure-enabled drug delivery system used by interventional radiologists in liver cancer procedures. Revenue of USD 12.9 million rose about 11% year over year, but management said growth fell short of its expectation. It said most of the shortfall came from new expansion territories, roughly one third of its field, where representatives took longer than planned to reach full productivity, while a smaller part reflected a faster shift to super selective Y90 treatment in small distal vessels. Accounts ordering TriNav rose by double digits year over year, and September was the strongest month of the year for ordering accounts and units.

TriNav Advance and Reimbursement Changes Shape the Outlook

In September the company received FDA clearance for TriNav Advance, which extends pressure-enabled delivery to small distal vessels through the physician's preferred microcatheter. A limited market release is being prepared, and management said the fourth-quarter guidance includes no revenue from it. On November 4, 2026, CMS published final calendar 2027 rules that management described as favorable. The national payment for the Y90 mapping angiogram code rises from about USD 11,874 to about USD 20,910, an increase of about 76%, and a new office-based lab code for PEDD embolization was set at about USD 13,788 per procedure. Both take effect January 1, 2027.

Cost Discipline, Cash Burn and the Evidence Program

Research and development spending fell to about USD 3.2 million from USD 5.7 million as nelitolimod trial costs did not recur, while sales and Marketing rose to about USD 10.7 million from USD 6.8 million on the larger field team, though it was down from USD 11.4 million in the second quarter. General and administrative expense fell to about USD 4.9 million from USD 6.1 million. Nine-month operating cash use was USD 21.9 million, and stockholders' Equity was only USD 0.7 million at September 30. The company has 11 active studies at 27 sites, with neuroendocrine and liver cancer studies due to start by year end and a publication of its randomized PEDIR study expected this year.

Where Things Stand

The reset reflects a sales-execution gap, not a revenue decline. TriSalus Life Sciences (NASDAQ:TLSI) still grew revenue 11% year over year to USD 12.9 million and widened its margin, but management revised its full-year outlook because new territories and super selective Y90 procedures were slower to contribute. The call did not state the earlier guidance range, so the size of the change cannot be calculated from the material. Next markers are a sequential step-up in the fourth quarter, the TriNav Advance limited release, 2027 guidance on the fourth-quarter call and nelitolimod data by year end.